Education
About Us
Working with TipRanks
Follow Us
Pulse Biosciences (PLSE)
NASDAQ:PLSE
Top Page
Pulse Biosciences
(NASDAQ:PLSE)
35Underperform
Pulse Biosciences (PLSE) vs. S&P 500 (SPY)
Market Cap
$1.07B
Dividend YieldN/A
Average Volume (3M)200.23K
Price to Earnings (P/E)―
Beta (1Y)2.35
Revenue GrowthN/A
EPS Growth-1.00%
CountryUS
Employees75
SectorHealthcare
Sector Strength78
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)-0.90
Shares Outstanding67,273,800
10 Day Avg. Volume278,455
30 Day Avg. Volume200,232
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-27.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Pulse Biosciences Business Overview & Revenue Model
Company DescriptionPulse Biosciences, Inc. is a medical technology company that focuses on developing and commercializing innovative therapeutic treatments leveraging its proprietary Nano-Pulse Stimulation (NPS) technology. Operating within the healthcare and medical device sectors, Pulse Biosciences aims to provide non-thermal, cellular-specific treatments for a range of dermatological and oncological conditions. The company's core product, the CellFX System, is designed to deliver precise energy pulses to treat benign and malignant lesions on the skin.
How the Company Makes MoneyPulse Biosciences generates revenue primarily through the sale and leasing of its CellFX System to dermatologists and other healthcare providers. The company may also earn revenue from service agreements, training, and support services related to the use of its systems. Additionally, Pulse Biosciences could engage in strategic partnerships or collaborations with other healthcare organizations to further expand the application of its technology and enhance its market presence. Key factors contributing to its earnings include the adoption and integration of its technology within clinical practices and potential expansion into international markets.
Pulse Biosciences Financial Statement Overview
Summary
Pulse Biosciences continues to face significant financial challenges, characterized by negative net income and reliance on external financing. Despite some improvements, such as reduced debt and increased cash reserves, the company struggles with profitability and operational efficiency.Income Statement
Pulse Biosciences has faced challenges in its income statement, marked by negative net income and EBIT over the periods reviewed. Despite a recent increase in revenue, the company still experiences negative gross and net profit margins. This indicates ongoing struggles with cost management and profitability, common in early-stage or high R&D-focused companies.30
Negative
Balance Sheet
The balance sheet shows a relatively stable equity position, with a notable reduction in debt levels over time. However, the company's ongoing losses have led to periods of negative equity, posing financial stability risks. The current equity ratio appears healthy, but the historical volatility and negative ROE highlight underlying financial challenges.45
Neutral
Cash Flow
Cash flow analysis reveals a consistent pattern of negative operating and free cash flow, indicating reliance on external financing to sustain operations. While there is a positive trend in cash reserves due to financing activities, the inability to generate positive cash flow from operations remains a critical concern for long-term sustainability.40
Negative
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 1.74M | 0.00 | 700.00K | 1.42M | 0.00 | 0.00 | Gross Profit |
| 604.00K | -1.21M | -11.24M | -550.00K | -665.00K | -666.00K | EBIT |
| -48.53M | -43.57M | -58.06M | -63.01M | -49.97M | -47.95M | EBITDA |
| -47.33M | -42.37M | -56.70M | -61.87M | -48.87M | -46.79M | Net Income Common Stockholders |
| -46.13M | -42.21M | -58.95M | -63.16M | -49.74M | -45.99M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 7.01M | 44.37M | 61.14M | 28.61M | 20.48M | 25.40M | Total Assets |
| 0.00 | 59.15M | 77.88M | 54.25M | 41.29M | 41.91M | Total Debt |
| 0.00 | 9.14M | 75.96M | 11.25M | 11.36M | 6.72M | Net Debt |
| 7.01M | -35.22M | 14.82M | -17.36M | -1.11M | -180.00K | Total Liabilities |
| 0.00 | 14.79M | 80.13M | 18.56M | 18.40M | 11.18M | Stockholders Equity |
| 16.07M | 44.36M | -2.25M | 35.69M | 22.89M | 30.74M |
| Cash Flow | Free Cash Flow | ||||
| -34.09M | -33.16M | -47.41M | -54.53M | -35.81M | -34.79M | Operating Cash Flow |
| -33.98M | -33.04M | -47.01M | -54.10M | -35.37M | -34.19M | Investing Cash Flow |
| -115.00K | -121.00K | -401.00K | 7.56M | 10.04M | -10.10M | Financing Cash Flow |
| 62.74M | 16.39M | 79.94M | 62.69M | 30.89M | 82.00K |
Pulse Biosciences Technical Analysis
Negative
14.53
Price Trends
18.54
Negative
18.41
Negative
17.42
Negative
Market Momentum
-0.75
Negative
38.69
Neutral
38.57
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PLSE, the sentiment is Negative. The current price of 14.53 is below the 20-day moving average (MA) of 16.36, below the 50-day MA of 18.54, and below the 200-day MA of 17.42, indicating a bearish trend. The MACD of -0.75 indicates Negative momentum. The RSI at 38.69 is Neutral, neither overbought nor oversold. The STOCH value of 38.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PLSE.
Pulse Biosciences Risk Analysis
Pulse Biosciences disclosed 61 risk factors in its most recent earnings report. Pulse Biosciences reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Pulse Biosciences Peers Comparison
Overall Rating
UnderperformOutperform
Sector (48)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $26.31B | 47.83 | 27.63% | ― | 11.34% | 4.24% | |
60 Neutral | $239.67M | ― | -38.45% | ― | 15.29% | 45.45% | |
51 Neutral | $1.05B | ― | -6.14% | ― | -20.89% | 83.44% | |
48 Neutral | $6.86B | 1.11 | -50.22% | 2.47% | 16.71% | 1.53% | |
46 Neutral | $2.30B | ― | -50.74% | ― | -7.03% | -20233.78% | |
35 Underperform | $1.07B | ― | -67.31% | ― | ― | -1.00% | |
35 Underperform | $3.10M | ― | 366.81% | ― | -30.19% | 97.74% |
* Healthcare Sector Average
Performance Comparison
PLSE
Pulse Biosciences
14.53
6.96
91.94%
CERS
Cerus
1.29
-0.58
-31.02%
DXCM
Dexcom
61.80
-77.13
-55.52%
QDEL
QuidelOrtho
32.49
-10.21
-23.91%
BLFS
BioLife Solutions
22.44
5.31
31.00%
TTOO
T2 Biosystems
0.12
-2.71
-95.76%
Pulse Biosciences Earnings Call Summary
Earnings Call Date: Mar 27, 2025 | % Change Since: -7.22% | Next Earnings Date: May 7, 2025
Earnings Call Sentiment Neutral
The earnings call highlighted significant progress in product development and commercialization, particularly in the advancement of their nsPFA technology. Financially, the company strengthened its balance sheet, although it also faced increased expenses and net losses. The sentiment of the call is balanced, with notable achievements in clinical and financial aspects, but also challenges in managing increased operational costs.Highlights
Advancements in Nanosecond PFA Technology
Pulse Biosciences is making progress in early commercialization steps with their Percutaneous Electrode for soft tissue ablation and executing clinical feasibility studies with the surgical clamp and 360 Catheter for atrial fibrillation treatment.
Successful Clinical Data Presentations
Clinical data from the nsPFA 360 Catheter was presented at the AF Symposium, and data on benign thyroid nodule ablation was presented at the American Thyroid Association and North American Society of Interventional Thyroidology.
Financial Strength and Strategy
The company raised an additional $47.9 million through warrant exercises related to a rights offering, strengthening their balance sheet with $118 million in cash and equivalents as of December 31, 2024.
Lowlights
Increased Expenses and Net Loss
Total GAAP costs and expenses increased by $7.7 million to $20.3 million, and the GAAP net loss was $19.4 million for the fourth quarter of 2024.
Operational Challenges
The increase in expenses was primarily driven by non-cash stock-based compensation, severance, and legal settlement expenses, indicating operational and administrative challenges.
Company Guidance
During the Pulse Biosciences Fourth Quarter 2024 Earnings Conference Call, CEO Paul LaViolette highlighted several key metrics and advancements. The company achieved seven FDA clearances, treated 6,000 patients, and secured FDA breakthrough device designation for its cardiac surgical clamp. Financially, total GAAP costs and expenses rose to $20.3 million from $12.5 million year-over-year, with non-GAAP costs reaching $11.3 million. The GAAP net loss increased to $19.4 million, while the non-GAAP net loss was $10.4 million. Importantly, Pulse Biosciences reinforced its balance sheet, ending 2024 with $118 million in cash and equivalents, driven by $47.9 million in net proceeds from warrant exercises related to the July 2024 rights offering.Pulse Biosciences Corporate Events
Executive/Board ChangesBusiness Operations and Strategy
Pulse Biosciences Strengthens Leadership with New CFO Appointment
Positive
Feb 4, 2025
Pulse Biosciences announced the appointment of Jon Skinner as Chief Financial Officer, effective February 3, 2025, to bolster its executive team as it scales the commercialization of its CellFX nanosecond PFA platform. Skinner, with extensive experience in financial leadership across healthcare and industrial sectors, brings strategic insights that are expected to aid in advancing Pulse Biosciences’ operational excellence and market positioning.
Product-Related AnnouncementsBusiness Operations and Strategy
Pulse Biosciences Updates Investors on Cardiac Innovations
Neutral
Jan 14, 2025
On January 14, 2025, Pulse Biosciences released an updated investor presentation on their website highlighting recent advancements in their cardiac treatment product line. This update is intended to inform investors and analysts about the progress in their product development programs, potentially impacting company operations and stakeholder decisions.
Executive/Board ChangesBusiness Operations and Strategy
Pulse Biosciences Appoints Paul LaViolette as CEO
Positive
Jan 13, 2025
Pulse Biosciences announced the appointment of Paul A. LaViolette as Chief Executive Officer and President, effective January 9, 2025. Mr. LaViolette, who has extensive experience in the healthcare and medical technology sectors, will also act as the principal executive and financial officer. This appointment comes with an at-will Employment Agreement, including stock options contingent on performance milestones. The announcement signals a strategic move to leverage Mr. LaViolette’s expertise to enhance the company’s positioning in the medical technology industry, particularly in its innovative nano-PFA technology development and market expansion efforts.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.